Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Cough In Idiopathic Pulmonary Fibrosis Ipf Epidemiology Forecast

DelveInsight’s ‘Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast– 2030’ report delivers an in-depth understanding of the cough in IPF, historical and forecasted epidemiology as well as the cough in IPF market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Cough in Idiopathic Pulmonary Fibrosis (IPF) Disease Understanding

Cough in Idiopathic Pulmonary Fibrosis (IPF) Overview

According to National Organization for Rare Disorders (NORD), IPF is classified as a form of idiopathic interstitial pneumonia, a group of lung diseases that damage the lungs similarly and occur due to unknown causes. This group of disorders is also known as diffuse parenchymal lung diseases. Collectively, these disorders are classified under the broader umbrella term, interstitial lung diseases (ILDs). ILDs are a large group of disorders (more than 200) characterized by progressive scarring of the lungs. IPF is the most common form.

 

Many patients with IPF complain of cough. Cough is a distressing and disabling symptom with a major impact on quality of life. The mechanism(s) causing cough in IPF are not fully known. In general, coughing is mediated by specific types of sensory neurons that can be activated through mechanical and/or chemical stimuli. In IPF, one potential explanation for this cough is that increased mechanical stress on the lungs caused by fibrosis may cause increased sensitivity to cough triggers. Another hypothesis is that fibrosed tissue may be more sensitive to chemical triggers. Finally, changes in mucus production and clearance may also affect patients’ susceptibility to cough, based on the observation that patients with IPF who have mutations in MUC5B tend to have a more severe cough.

 

In general, chronic cough can impact severely on different aspects of life. Problems with sleeping, raucous vocal sounds, and musculoskeletal pain of the chest can occur. Chronic cough can cause relationship difficulties, avoidance of public areas, decreased social interaction, and work-related problems affecting physical, mental, and social health.

Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of IPF and Prevalent Population of Cough in IPF in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.

 

Key Findings

This section provides glimpse of the cough in IPF epidemiology in the 7MM.

  • The total prevalent population of cough in IPF in the 7MM in 2020 is 184,445 and is expected to rise during the study period (2018–2030).
  • Epidemiology assessed for cough in IPF showed that the US, in 2020, accounted for approximately 113,921 prevalent cases.
  • Among the EU-5 countries in 2020, the UK had the highest prevalent population of cough in IPF patients with 26,950 cases, followed by Italy (13,916) and Germany (10,194). In contrast, Spain had the lowest cases (4,576) in 2020.
  • Japan accounted for 10,186 prevalent cough in IPF cases in 2020.

Country Wise- Cough in IPF Epidemiology

The epidemiology segment also provides the cough in IPF epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Scope of the Report

  • The report covers the descriptive overview of cough in IPF, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of cough in IPF.

Report Highlight

  • Ten Year Forecast of cough in IPF
  • 7MM Coverage
  • Delvelnsight has analysed Diagnosed Prevalent Population of IPF in the 7MM which suggests that the patient pool will increase during the forecast period of 2021–2030.
  • The scope of the report also encompasses Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients was observed to be 184,445 in 2020 which is anticipated to increase during the forecast period of 2021–2030.

Analyst Comments

  • The epidemiology for cough in IPF has been derived from the patient pool of IPF in each country. Even though most individuals with IPF present cough as a common symptom, studies pertaining to the epidemiology of cough in IPF are limited, through research and analysis, it can be concluded that the etiology and mechanism of cough associated with IPF are poorly understood.
  • Moreover, it has been noted that various large-scale epidemiologic studies have been conducted predominantly in Western countries. Data from Asian countries is limited.
  • Additionally, data on incidence, prevalence, and mortality of IPF are sparse and vary across studies. DelveInsight has carefully analyzed the available data to forecast the epidemiological data for cough in IPF.

Key Questions Answered

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of cough in IPF?
  • What is the historical cough in IPF patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of cough in IPF in the 7MM?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to cough in IPF?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of cough in IPF during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

  • The Cough in IPF report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM cough in IPF market.
  • Quantify patient share distribution in the 7MM for cough in IPF.
  • The cough in IPF epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The cough in IPF epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the Ten-year forecast period using reputable sources.

1. Key Insights

2. Report Introduction

3. Executive Summary of Cough in Idiopathic Pulmonary Fibrosis (IPF)

4. Key Events

5. SWOT Analysis

6. Disease Background and Overview

6.1. Introduction

6.2. Signs and Symptoms of Idiopathic Pulmonary Fibrosis

6.3. Causes and Risk Factors of Idiopathic Pulmonary Fibrosis

6.4. Prognosis of Idiopathic Pulmonary Fibrosis

6.5. Cough in Idiopathic Pulmonary Fibrosis

6.5.1. Characteristics and Demographics of Chronic Cough

6.5.2. Effect on the Patient

6.5.3. Pathophysiology of chronic cough

6.5.4. Mechanism of Cough in Idiopathic Pulmonary Fibrosis

6.5.5. Comorbidities Influencing Cough

6.6. Living with Idiopathic Pulmonary Fibrosis

6.6.1. Living With the Cough Associated with Pulmonary Fibrosis

6.7. Assessment of Cough

7. French Practical guidelines for the diagnosis and management of IPF (2017)

8. NICE guidelines on IPF in adults: diagnosis and management (2017)

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Epidemiology Methodology

9.3. 7MM Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients

9.4. Assumptions and Rationale

9.4.1. United States

9.4.2. EU5

9.4.3. Japan

9.5. The United States

9.5.1. Total Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in the United States

9.5.2. Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in the US

9.6. EU5

9.6.1. Germany

9.6.1.1. Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Germany

9.6.1.2. Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in Germany

9.6.2. France

9.6.2.1. Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in France

9.6.2.2. Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in France

9.6.3. Italy

9.6.3.1. Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Italy

9.6.3.2. Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in Italy

9.6.4. Spain

9.6.4.1. Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Spain

9.6.4.2. Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in Spain

9.6.5. UK

9.6.5.1. Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in the UK

9.6.5.2. Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in UK

9.7. Japan

9.7.1. Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Japan

9.7.2. Prevalent Population of Cough in Idiopathic Pulmonary Fibrosis (IPF) patients in Japan

10. Organizations contributing towards Cough in IPF

11. Patient Journey

12. Appendix

12.1. Bibliography

13. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Table

Table 1: Summary of Cough in IPF Market, and Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Assessment of Cough in IPF

Table 4: 7MM Prevalent Population of cough in IPF patients (2018–2030)

Table 5: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in the US (2018–2030)

Table 6: Prevalent Population of cough in IPF patients in the United States (2018–2030)

Table 7: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Germany (2018–2030)

Table 8: Prevalent Population of cough in IPF patients in Germany (2018–2030)

Table 9: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in France (2018–2030)

Table 10: Prevalent Population of cough in IPF patients in France (2018–2030)

Table 11: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Italy (2018–2030)

Table 12: Prevalent Population of cough in IPF patients in Italy (2018–2030)

Table 13: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Spain (2018–2030)

Table 14: Prevalent Population of cough in IPF patients in Spain (2018–2030)

Table 15: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in the UK (2018–2030)

Table 16: Prevalent Population of cough in IPF patients in UK (2018–2030)

Table 17: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Japan (2018–2030)

Table 18: Prevalent Population of cough in IPF patients in Japan (2018–2030)

Table 19: Organizations contributing toward IPF

List of Figures

Figure 1: Risk Factors Associated With IPF

Figure 2: Pathophysiology of Cough

Figure 3: Mechanism of Cough in IPF

Figure 4: 7MM Prevalent Population of cough in IPF patients (2018–2030)

Figure 5: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in the United States

Figure 6: Prevalent Population of cough in IPF patients in the US (2018–2030)

Figure 7: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Germany (2018–2030)

Figure 8: Prevalent Population of cough in IPF patients in Germany (2018–2030)

Figure 9: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in France (2018–2030)

Figure 10: Prevalent Population of cough in IPF patients in France (2018–2030)

Figure 11: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Italy (2018–2030)

Figure 12: Prevalent Population of cough in IPF patients in Italy (2018–2030)

Figure 13: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Spain (2018–2030)

Figure 14: Prevalent Population of cough in IPF patients in Spain (2018–2030)

Figure 15: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in the UK (2018–2030)

Figure 16: Prevalent Population of cough in IPF patients in UK (2018–2030)

Figure 17: Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in Japan (2018–2030)

Figure 18: Prevalent Population of cough in IPF patients in Japan (2018–2030)

Forward to Friend

Need A Quote